GlassScriptPhysician profile
Arnold Greenberg
NPI 1780616177
$18,121.81
in general payments reported to CMS, 2019-2025
52 companies · $1,636 in 2025
The $1,636 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,969 · 2020: $2,341 · 2021: $3,577 · 2022: $2,713 · 2023: $3,192 · 2024: $2,693 · 2025: $1,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,325 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,324.58 |
| Education | $196.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,809.48 | 2019-2025 | Ajovy, Austedo, Austedo Xr |
| Ucb, INC. | $1,635.22 | 2019-2025 | Briviact, Nayzilam |
| Sk Life Science, INC. | $1,432.27 | 2020-2025 | Xcopri |
| Abbvie INC. | $1,262.68 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,088.46 | 2019-2025 | Ingrezza, Ongentys |
| Eisai INC. | $810.85 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $794.13 | 2019-2025 | Rytary, Crexont |
| Lilly USA, LLC | $706.21 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Avanir Pharmaceuticals, INC. | $627.31 | 2019-2022 | |
| Pfizer INC. | $601.05 | 2023-2025 | |
| Biogen, INC. | $587.50 | 2020-2023 | Vumerity, Tysabri, Avonex |
| Amgen INC. | $522.74 | 2019-2023 | Aimovig |
| Catalyst Pharmaceuticals, INC. | $511.17 | 2023-2024 | Fycompa |
| Lundbeck LLC | $492.12 | 2019-2024 | Vyepti, Rexulti |
| Biohaven Pharmaceuticals, INC. | $490.63 | 2020-2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnold Greenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.